Pfizer reports Q3 vaccine sales decline amid challenging US market conditions

Comirnaty, Pfizer’s COVID-19 prevention vaccine, reported global sales of $1.15 billion

MSD secures $700 million boost from Blackstone to advance broad-cancer ADC therapy Sac-TMT

Amgen confident in US biosimilar market’s strength as sales surge 52%

Philips reiterates FY25 outlook following steady Q3 performance

Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year

Sovato secures series B funding to advance remote robotic surgery platform

The company plans to use the funds to enhance its technology and forge new strategic partnerships with surgical robotics companies

Teva reports 11th consecutive quarter of growth

Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.

Industry leaders call for a new era of collaboration, innovation, and self-reliance

Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence

FDA rejects Regeneron’s Eylea HD pre-filled syringe application amid manufacturing setbacks

FDA issues warning letter to Philips over manufacturing and quality system deficiencies

The FDA’s review also revealed delays in Philips’ internal investigations, with 54 inquiries failing to meet targeted completion dates—23 of which were delayed by more than 100 days

GSK signs $745 million licensing agreement with Empirico for novel respiratory siRNA therapy

The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio